Mohamed Hazem M. Ibrahim

Mohamed Hazem M. Ibrahim

Auto-generated profile, based on publicly available information

Mohamed Hazem M. Ibrahim

Zagazig University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in American Journal of Animal and Veterinary Sciences
Verified
Journal Article
Open access
PDF file
IRI. A. Radwan
I. A. Radwan
Ahmed AbedAhmed Abed
Ahmed Abed
MAM. R. Abeer
M. R. Abeer
MIM. A. Ibrahim
M. A. Ibrahim
AAA. S. Abdallah
A. S. Abdallah

25 October 2024 in Nutritional Neuroscience
Verified
Journal Article
Closed access
MMMohamed Ezzat M. Mansour
Mohamed Ezzat M. Mansour
AAAhmed Hamdy G. Ali
Ahmed Hamdy G. Ali
MIMohamed Hazem M. Ibrahim
Mohamed Hazem M. Ibrahim
AMAhella Ismail A. Mousa
Ahella Ismail A. Mousa
Ahmed NegidaAhmed Negida
Ahmed Negida
Alzheimer's disease (AD) is the most common neurodegenerative disorder. A key factor in its pathogenesis is the dysfunction of the N-methyl-D-aspartate (NMDA) receptor due to D-serine degradation by D-amino acid oxidase. Benzoate has been suggested to enhance NMDA receptor function, potentially benefiting early-phase AD. This study aimed to synthesize evidence from randomized clinical trials (RCTs) on the safety and efficacy of sodium benzoate in AD patients. We followed PRISMA statement guidelines during the accommodation of this systematic review and meta-analysis. A computer literature search (PubMed, Scopus, Web of Science, and Cochrane Central) was conducted. We included RCTs that compared sodium benzoate with placebo regarding cognitive functions. The primary outcome measure was the Alzheimer's disease assessment scale-cognitive subscale, pooled as the mean difference between the two groups from baseline to the endpoint. The secondary outcomes measures are the clinician's interview-based impression of change plus caregiver input, catalase, and superoxide dismutase antioxidants. Three RCTs (described in four articles) with 306 patients were included in this study. Sodium benzoate significantly improved the ADAS-cog score compared with placebo (MD -2.13 points, 95% CI [-3.35 to -0.90]; P= 0.0007). Sodium benzoate is a safe drug that may improve cognitive function in patients with early-stage Alzheimer's disease. However, the significant effect arises primarily from one small study, highlighting the need for caution in interpretation. Further research with larger sample sizes and longer durations is necessary to validate these findings and assess safety and efficacy.